Tools chosen: kalshi_direct kalshi_related polymarket_related claude_news claude_news gdelt_news earnings_data wikipedia code_execution

Sub-questions (Fermi decomposition)

Planner reasoning

This is a Kalshi-sourced pharma-regulatory timing question, so the market price is the primary anchor, supplemented by the concrete regulatory calendar for COMPASS Pathways' COMP360 (Phase 3 COMP005/COMP006 readouts, NDA submission timing, priority-review/PDUFA math, plus DEA rescheduling steps). The decisive empirical facts are company-guided milestone dates and typical FDA review durations, which determine whether an approval could plausibly land before July 1, 2027.

# Current state COMPASS Pathways is conducting a rolling NDA submission for COMP360 psilocybin (TRD) under FDA-granted rolling review, with final NDA completion guided for Q4 2026; a Commissioner's National Priority Voucher (CNPV, awarded April 2026) could compress the review clock to just 1–2 months post-completion. No PDUFA date has yet been set. The Kalshi market resolves YES if FDA approval occurs before July 1, 2027 — DEA rescheduling and commercial launch are separate, later steps not required for resolution. # Timeline of key events - 2024-08-09: FDA rejects Lykos Therapeutics' MDMA NDA for PTSD; adcomm voted 9-2 against, citing functional unblinding, incomplete REMS strategy (confirmed, hklaw.com). - 2024-10: Compass lays off 30% of staff, narrows focus after Lykos rejection (confirmed, Wikipedia). - 2026 (date unspecified, "first Phase 3 trial"): COMP005 met primary endpoint (~25% response) (confirmed, Compass IR). - 2026 (date unspecified, prior to April): FDA grants Compass rolling NDA submission/review request following positive regulatory meeting (confirmed, Compass IR/SEC). - 2026-04-18: Trump signs executive order directing agencies to accelerate psychedelic drug approvals (confirmed, medicaldaily.com). - 2026-04-24: FDA Commissioner Makary issues CNPVs to three psychedelic programs, including Compass, compressing review to 1–2 months (confirmed, medicaldaily.com/pharmexec). - 2026 (Q2, second Phase 3 trial): COMP006 meets primary endpoint (MADRS diff -3.8, p<0.001; 39% response) (confirmed, Compass IR). - 2026-07-07: Compass releases 26-week durability data from COMP006; reiterates NDA modules being submitted, final completion targeted Q4 2026 (confirmed, Compass IR). - 2026-07-14: FDA finalizes guidance addressing "functional unblinding" issue from Lykos rejection (confirmed, techtimes.com). - 2026 (Q2 earnings): Compass reports $466M cash, runway into 2028; commercial launch-readiness on track for end-2026, H1 2027 launch target (confirmed, SEC filing). - 2026-08-19: FDA announces public hearing on psychedelic therapeutics, finalizes clinical guidance (confirmed, mondaq.com). - Ongoing (as of research date, ~2026-08): No confirmed PDUFA date; final NDA not yet complete/accepted (reported, merlintrader.com). # Event Will the FDA approve COMP360 psilocybin for Treatment-Resistant Depression before July 1, 2027? # Outcomes to forecast Yes / No # Kalshi market anchor **Current YES price: 79%** (30-day change: +4pts; 7-day: +1pt). Range 69–94% over 25 data points; thin liquidity (avg. 61 contracts/day). Trend has been gradually rising, consistent with positive Phase 3 readouts and CNPV news. # Sub-question answers 1. **Guided timeline for readouts/NDA** — Both COMP005 and COMP006 26-week data released by July 2026; company guidance is final NDA (rolling) completion in Q4 2026 (Compass IR). 2. **Did pivotal trials meet endpoints?** — Yes, both met primary endpoints: COMP006 MADRS diff -3.8 vs. placebo (p<0.001), 39% responder rate; COMP005 ~25% responder rate (Compass IR). 3. **PDUFA timing math** — Standard: 60-day filing + 10mo review ≈ 12mo post-completion (would land ~Oct 2027, after cutoff). Priority (6mo): ~8mo post-completion (~June 2027, borderline). CNPV promises just 1–2 months post-complete-filing, which if honored lands well before July 2027 even from a Q4 2026 completion (claude_news, pharmexec.com). 4. **BTD/priority review status** — COMP360 holds Breakthrough Therapy Designation and now also a CNPV, both supporting expedited/compressed review (merlintrader.com, Wikipedia). 5. **Lykos precedent** — Aug 2024 rejection driven by functional unblinding and unresolved REMS plan; adcomm voted 9-2 against. FDA's July 2026 guidance formally addresses unblinding via active placebo/blinding-questionnaire requirements, but uncertainty remains whether FDA will convene an adcomm for Compass (psychedelicbeacon.com, techtimes.com). 6. **Cash/manufacturing readiness** — $466M cash at Q1 2026, runway into 2028; launch-readiness targeted for end-2026 (SEC filing). 7. **Historical base rate** — Not directly quantified in research; Monte Carlo model proxy estimates ~55–81% depending on submission timing/review type (code_execution). # Key facts (high-confidence, factual) 1. [Compass IR] Both Phase 3 trials (COMP005, COMP006) met primary endpoints. 2. [Compass IR/SEC] Rolling NDA submission underway; final completion targeted Q4 2026. 3. [pharmexec.com] CNPV awarded April 2026, targets 1–2 month review post-complete filing. 4. [Wikipedia] COMP360 holds FDA Breakthrough Therapy Designation. 5. [SEC filing] $466M cash, runway into 2028. 6. [hklaw.com] Lykos MDMA NDA rejected Aug 2024 on unblinding/REMS grounds — same regulatory class faces heightened scrutiny. 7. [techtimes.com] FDA finalized clinical guidance (July 2026) addressing the unblinding issue underlying the Lykos rejection. # Cross-market signals - Kalshi related: MDMA-for-PTSD (before 2030) trades at 56% — reflects lingering Lykos-driven skepticism for psychedelics broadly, but longer horizon. - Polymarket: No matching markets found. - Sportsbook implied: N/A (not applicable to FDA approvals). # Analyst opinions and speculation - Stifel/analyst commentary (Mar 2026): PDUFA projected late 2026–2027, priority review expected (investing.com). - Psychedelic Beacon tracker: earliest realistic decision Q4 2026/Q1 2027, contingent on Q4 NDA completion and CNPV 1–2 month goal holding (psychedelicbeacon.com). - Uncertainty flagged: whether FDA convenes an advisory committee (Lykos precedent) and whether CNPV timeline holds in practice for a psychedelic (psychedelicbeacon.com). - Monte Carlo model (code_execution): P(Yes) ≈ 81% if NDA fully submitted by mid-2026; ≈55% if completion slips to Q4 2026 under standard priority-review assumptions (note: model used 6-month priority clock, likely conservative vs. CNPV's 1–2 month promise). # Directional lean per outcome - **Yes**: Positive Phase 3 data on both trials, BTD + CNPV compressing review to 1–2 months, rolling NDA already underway, strong cash position, explicit H1 2027 company launch guidance, Kalshi trending up (+4pts/30d) to 79%. - **No**: No confirmed PDUFA date yet; final NDA completion not until Q4 2026 at earliest; Lykos precedent shows adcomm/CRL risk for psychedelics; unresolved whether CNPV's 1-2 month goal will actually apply/hold; refuse-to-file or first-cycle CRL would push past cutoff (per Monte Carlo, CRL scenarios "never" resolve before July 2027). # Gaps / unknowns - No confirmed NDA completion date or PDUFA date as of research cutoff (~Aug 2026). - Unclear whether FDA will convene an advisory committee for COMP360. - Unclear whether CNPV's 1–2 month review promise will hold in practice for a first-of-class psychedelic. - REMS strategy readiness for Compass not detailed in research. # Calibration anchors - Kalshi current YES price (anchor): **79%** - Monte Carlo scenario closest to current guided timeline (Q4 2026 submission): ~55% under conservative (6-month priority clock) assumptions; up to ~81-90%+ if CNPV's 1-2 month goal is credited fully — Kalshi's 79% sits between these, reflecting market weighting toward CNPV effectiveness. - Precedent: Lykos MDMA rejected 2024 despite BTD and strong data — a cautionary base rate for psychedelic-class NDAs facing adcomm scrutiny.

1. Both forecasts converge tightly around the Kalshi anchor (75%/78% vs 79%) without independently stress-testing the CNPV assumption — since the brief explicitly flags CNPV's 1-2 month clock as "unproven for a first-of-class psychedelic" and the Monte Carlo model's conservative scenario gives only ~55%, neither forecaster explains why they weight the optimistic CNPV scenario so heavily (~75-90%) rather than blending toward the midpoint or lower. 2. Neither forecast adequately grapples with "refuse-to-file" risk given that final NDA completion is only *guided* for Q4 2026 with no confirmed completion date as of Aug 2026 — if completion slips even to Q1 2027, even a compressed 1-2 month CNPV review could push resolution past July 1, 2027, a scenario the Monte Carlo explicitly flags as "never resolves before July 2027" under CRL/slippage. 3. The Lykos precedent is treated as a modest headwind by both, but the brief notes the rejection came via a 9-2 adcomm vote despite the drug having BTD too — neither forecaster explicitly estimates the probability FDA convenes an adcomm for COMP360, which is flagged as a genuine unknown ("unclear whether FDA will convene an advisory committee") and could independently add months regardless of CNPV. 4. Both forecasts cite the July 2026 guidance addressing "functional unblinding" as de-risking the Lykos-style rejection, but neither questions whether Compass's specific trial design (COMP005/006) actually satisfies the new guidance's active-placebo/blinding-questionnaire requirements — this is an unverified assumption of compliance, not confirmed fact. 5. Neither forecaster flags the political/regulatory tail risk from the unusual April 2026 executive order and CNPV mechanism itself — a novel, untested expedited pathway created by executive action could face legal challenge, funding disputes, or reversal, which is a scenario absent from both rationales despite being a structurally unprecedented lever this market depends on. 6. Both largely ignore sub-question 7 (base rate ~55-81%) as a wide, low-confidence range and don't reconcile why their point estimates land near the top of that range rather than nearer the middle, especially given thin market liquidity (61 contracts/day) that could make the 79% Kalshi price itself noisy/unreliable as an anchor.

72% (66% confidence)

Yes: 72% No: 28%

The fundamentals are strongly supportive: two positive Phase 3 readouts, a rolling NDA underway with Q4 2026 completion guidance, BTD plus an April 2026 CNPV promising a 1–2 month review, ample cash, and explicit H1 2027 launch guidance. However, the red-team critique is partly valid — both forecasters anchored on a thin-liquidity 79% price while implicitly crediting the untested CNPV clock at ~85–90%. A bottom-up build (P(CNPV compression actually delivers) ~0.7–0.8; if instead standard priority review applies, a Q4 2026 completion lands ~Aug–Oct 2027 and misses; plus ~15% first-cycle CRL/adcomm risk carried over from the Lykos precedent and unverified REMS/blinding-guidance compliance) yields roughly 0.65–0.70. I therefore settle modestly below both forecasts and the market anchor at 72%, respecting the market's information but discounting for structural novelty of the CNPV pathway and unconfirmed NDA completion/PDUFA dates.

Total pipeline time: 172.9s